Kamada (KMDA) Non Operating Income (2012 - 2026)
Kamada (KMDA) posted quarterly Non Operating Income of $1.6 million for Q1 2026, up 32.15% year-on-year from $1.2 million in Q1 2025, and up 232.04% on a QoQ basis from -$1.2 million in Q4 2025.
Kamada (KMDA) Non Operating Income (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non Operating Income for 15 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- Quarterly Non Operating Income rose 32.15% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 44.14% YoY) and the FY2025 annual result came in at $2.8 million, down 58.82% from the prior year.
- Non Operating Income advanced to $1.6 million in Q1 2026 per KMDA's latest filing, from -$1.2 million in the prior quarter.
- Over the last five years, Non Operating Income for KMDA reached as high as $2.6 million in Q4 2024 and fell as low as -$2.2 million in Q4 2023.
- A 5-year average of $828444.4 and a median of $1.2 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 729.41% — and 2023, when it sank 309.7%.
- Year by year, Non Operating Income stood at $1.1 million in 2022, then plunged by 309.7% to -$2.2 million in 2023, then jumped by 216.5% to $2.6 million in 2024, then plunged by 145.17% to -$1.2 million in 2025, then soared by 232.04% to $1.6 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.6 million, -$1.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 2.62 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Dec 31, 2023 | -2.25 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 1.36 Mn |
| Jun 30, 2021 | 537,000.00 |
| Mar 31, 2021 | -323,000.00 |
| Dec 31, 2020 | 739,000.00 |
| Jun 30, 2020 | 1.42 Mn |
| Mar 31, 2020 | -774,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Jun 30, 2019 | -195.00 |
| Mar 31, 2019 | 156,000.00 |
| Dec 31, 2018 | -417,000.00 |
| Jun 30, 2018 | -129.00 |